| Javier Emilio Marinez, MD | |
|
685 Palm Springs Dr, Suite 2a, Altamonte Springs, FL 32701-7853 | |
| (407) 830-5577 | |
| (407) 830-4164 |
| Full Name | Javier Emilio Marinez |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 24 Years |
| Location | 685 Palm Springs Dr, Altamonte Springs, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679696983 | NPI | - | NPPES |
| 004262500 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | ME96871 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventhealth Orlando | Orlando, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Infectious Disease Consultants Md Pa | 3375531320 | 21 |
News Archive
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.
About two-thirds of maternal deaths, newborn deaths and stillbirths could be prevented by 2035 if the current level of care by professional midwives educated and regulated to international standards was scaled up to provide universal access, finds a new study led by the United Nations Population Fund, WHO, and the International Confederation of Midwives published today in the Lancet Global Health.
What you're reading now secretly tells you whether your country will be skinnier or fatter in three years. After analyzing 50 years of all the food words mentioned in major newspapers like the New York Times and London Times, a new Cornell study shows that the food words trending today in 2015 will predict a country's obesity level in three years - in 2018.
Cerenis Therapeutics SA, a privately held biopharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced it will present the results of two clinical proof-of-concept studies for its CER-627 program (niacin/aspirin combinations) at the 78th European Atherosclerosis Society Congress on June 20-23 in Hamburg, Germany.
Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding.
› Verified 5 days ago
| Entity Name | Infectious Disease Consultants Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407873581 PECOS PAC ID: 3375531320 Enrollment ID: O20040506000341 |
News Archive
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.
About two-thirds of maternal deaths, newborn deaths and stillbirths could be prevented by 2035 if the current level of care by professional midwives educated and regulated to international standards was scaled up to provide universal access, finds a new study led by the United Nations Population Fund, WHO, and the International Confederation of Midwives published today in the Lancet Global Health.
What you're reading now secretly tells you whether your country will be skinnier or fatter in three years. After analyzing 50 years of all the food words mentioned in major newspapers like the New York Times and London Times, a new Cornell study shows that the food words trending today in 2015 will predict a country's obesity level in three years - in 2018.
Cerenis Therapeutics SA, a privately held biopharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced it will present the results of two clinical proof-of-concept studies for its CER-627 program (niacin/aspirin combinations) at the 78th European Atherosclerosis Society Congress on June 20-23 in Hamburg, Germany.
Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Javier Emilio Marinez, MD 685 Palm Springs Dr, Suite 2a, Altamonte Springs, FL 32701-7853 Ph: (407) 830-5577 | Javier Emilio Marinez, MD 685 Palm Springs Dr, Suite 2a, Altamonte Springs, FL 32701-7853 Ph: (407) 830-5577 |
News Archive
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.
About two-thirds of maternal deaths, newborn deaths and stillbirths could be prevented by 2035 if the current level of care by professional midwives educated and regulated to international standards was scaled up to provide universal access, finds a new study led by the United Nations Population Fund, WHO, and the International Confederation of Midwives published today in the Lancet Global Health.
What you're reading now secretly tells you whether your country will be skinnier or fatter in three years. After analyzing 50 years of all the food words mentioned in major newspapers like the New York Times and London Times, a new Cornell study shows that the food words trending today in 2015 will predict a country's obesity level in three years - in 2018.
Cerenis Therapeutics SA, a privately held biopharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced it will present the results of two clinical proof-of-concept studies for its CER-627 program (niacin/aspirin combinations) at the 78th European Atherosclerosis Society Congress on June 20-23 in Hamburg, Germany.
Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding.
› Verified 5 days ago
Jaime Carrizosa, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 685 Palm Springs Dr, Ste. 2a, Altamonte Springs, FL 32701 Phone: 407-830-5577 Fax: 407-830-4164 | |
Dr. Walter Lamar Seifert, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 258 E Altamonte Dr Ste 1000, Altamonte Springs, FL 32701 Phone: 407-212-5589 | |
Dr. Fuad Afzal, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 631 Palm Springs Dr, Suite 104, Altamonte Springs, FL 32701 Phone: 407-265-2540 Fax: 407-265-9167 | |
Robert B Reynolds, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 894 E Altamonte Dr, Altamonte Springs, FL 32701 Phone: 407-834-5151 Fax: 407-834-5562 | |
Raul C Castillo, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 894 E Altamonte Dr, Altamonte Springs, FL 32701 Phone: 407-834-5151 Fax: 407-896-1926 | |
Fernando Alvarado, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 685 Palm Springs Dr, Ste 2a, Altamonte Springs, FL 32701 Phone: 407-830-5577 Fax: 407-830-4164 | |
Dr. Udit Joshi, MD, FACC Infectious Disease Medicare: Medicare Enrolled Practice Location: 450 W Central Pkwy, Altamonte Springs, FL 32714 Phone: 407-767-8554 |